Department of Pharmacology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
Department of Neurobiology and Anatomy, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
Br J Pharmacol. 2018 Oct;175(19):3758-3772. doi: 10.1111/bph.14445. Epub 2018 Aug 12.
We have demonstrated that i.c.v.-administered (±)-epibatidine, a nicotinic ACh receptor (nAChR) agonist, induced secretion of noradrenaline and adrenaline (catecholamines) from the rat adrenal medulla with dihydro-β-erythroidin (an α4β2 nAChR antagonist)-sensitive brain mechanisms. Here, we examined central mechanisms for the (±)-epibatidine-induced responses, focusing on brain NOS and NO-mediated mechanisms, soluble GC (sGC) and protein S-nitrosylation (a posttranslational modification of protein cysteine thiol groups), in urethane-anaesthetized (1.0 g·kg , i.p.) male Wistar rats.
(±)-Epibatidine was i.c.v. treated after i.c.v. pretreatment with each inhibitor described below. Then, plasma catecholamines were measured electrochemically after HPLC. Immunoreactivity of S-nitrosylated cysteine (SNO-Cys) in α4 nAChR subunit (α4)-positive spinally projecting neurones in the rat hypothalamic paraventricular nucleus (PVN, a regulatory centre of adrenomedullary outflow) after i.c.v. (±)-epibatidine administration was also investigated.
(±)-Epibatidine-induced elevation of plasma catecholamines was significantly attenuated by L-NAME (non-selective NOS inhibitor), carboxy-PTIO (NO scavenger), BYK191023 [selective inducible NOS (iNOS) inhibitor] and dithiothreitol (thiol-reducing reagent), but not by 3-bromo-7-nitroindazole (selective neuronal NOS inhibitor) or ODQ (sGC inhibitor). (±)-Epibatidine increased the number of spinally projecting PVN neurones with α4- and SNO-Cys-immunoreactivities, and this increment was reduced by BYK191023.
Stimulation of brain nAChRs can induce elevation of plasma catecholamines through brain iNOS-derived NO-mediated protein S-nitrosylation in rats. Therefore, brain nAChRs (at least α4β2 subtype) and NO might be useful targets for alleviation of catecholamines overflow induced by smoking.
我们已经证明,脑室内给予(±)-依匹巴特idine(一种烟碱型乙酰胆碱受体[nAChR]激动剂)可通过二氢-β-erythroidin(一种α4β2 nAChR 拮抗剂)敏感的脑机制诱导大鼠肾上腺髓质释放去甲肾上腺素和肾上腺素(儿茶酚胺)。在这里,我们研究了(±)-依匹巴特idine 诱导反应的中枢机制,重点关注脑NOS 和 NO 介导的机制、可溶性 GC(sGC)和蛋白 S-亚硝化(一种蛋白质半胱氨酸硫醇基团的翻译后修饰),在氨基甲酸乙酯麻醉(1.0 g·kg-1,ip)雄性 Wistar 大鼠中。
(±)-依匹巴特idine 在脑室内预处理以下每种抑制剂后进行脑室内处理。然后,通过 HPLC 电化学测量血浆儿茶酚胺。在脑室内给予(±)-依匹巴特idine 后,还研究了大鼠下丘脑室旁核(PVN,肾上腺髓质流出的调节中心)中 α4 nAChR 亚基(α4)阳性投射神经元中 S-亚硝化半胱氨酸(SNO-Cys)的免疫反应性。
(±)-依匹巴特idine 诱导的血浆儿茶酚胺升高明显被 L-NAME(非选择性 NOS 抑制剂)、羧基-PTIO(NO 清除剂)、BYK191023[选择性诱导型 NOS(iNOS)抑制剂]和 DTT(硫醇还原剂)减弱,但不受 3-溴-7-硝基吲唑(选择性神经元 NOS 抑制剂)或 ODQ(sGC 抑制剂)的影响。(±)-依匹巴特idine 增加了具有α4 和 SNO-Cys 免疫反应性的投射到脊髓的 PVN 神经元的数量,而这种增加被 BYK191023 减少。
脑 nAChRs 的刺激可通过脑内 iNOS 衍生的 NO 介导的蛋白质 S-亚硝化诱导大鼠血浆儿茶酚胺升高。因此,脑 nAChRs(至少是α4β2 亚型)和 NO 可能是缓解吸烟引起的儿茶酚胺溢出的有用靶点。